APB890Hu01 200µg Active Apolipoprotein C3 (APOC3) Organism Species: *Homo sapiens* (Human) *Instruction manual*

FOR RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1st Edition (Apr, 2016)

[PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Ser21~Ala99

Tags: Two N-terminal Tags, His-tag and SUMO-tag

Purity: >95%

Endotoxin Level: <1.0EU per 1µg (determined by the LAL method).

Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.01% sarcosyl and 5% trehalose.

Applications: Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 5.8

Predicted Molecular Mass: 22.5kDa

Accurate Molecular Mass: 21kDa as determined by SDS-PAGE reducing conditions.

Phenomenon explanation:

The possible reasons that the actual band size differs from the predicted are as follows:

- 1. Splice variants: Alternative splicing may create different sized proteins from the same gene.
- 2. Relative charge: The composition of amino acids may affects the charge of the protein.
- 3. Post-translational modification: Phosphorylation, glycosylation, methylation etc.
- 4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved to give the active form.
- 5. Polymerization of the target protein: Dimerization, multimerization etc.

[<u>USAGE</u>]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

SEAEDASLLS FMQGYMKHAT KTAKDALSSV QESQVAQQAR GWVTDGFSSL KDYWSTVKDK FSEFWDLDPE VRPTSAVAA

[ACTIVITY]

Apolipoprotein C3 (APOC3) also known as Apolipoprotein C-III is is a component of very low density lipoprotein (VLDL). APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to inhibit hepatic uptake of triglyceride-rich particles. An increase in APOC3 levels induces the development of hypertriglyceridemia. Besides, Apolipoprotein A1 (APOA1) has been identified as an interactor of APOC3, thus a binding ELISA assay was conducted to detect the interaction of recombinant human APOC3 and recombinant human APOA1. Briefly, APOC3 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to APOA1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-APOC3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary

antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37° C. Finally, add 50μ L stop solution to the wells and read at 450nm immediately. The binding activity of APOC3 and APOA1 was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of APOC3 with APOA1.




Figure 2. Gene Sequencing (extract)




Figure 3. SDS-PAGE

Sample: Active recombinant APOC3, Human




Figure 4. Western Blot

Sample: Recombinant APOC3, Human;

Antibody: Rabbit Anti-Human APOC3 Ab (PAB890Hu01)

[<u>IMPORTANT NOTE</u>]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.